ATE546448T1 - Urotensin-ii-rezeptorantagonisten - Google Patents
Urotensin-ii-rezeptorantagonistenInfo
- Publication number
- ATE546448T1 ATE546448T1 AT09791047T AT09791047T ATE546448T1 AT E546448 T1 ATE546448 T1 AT E546448T1 AT 09791047 T AT09791047 T AT 09791047T AT 09791047 T AT09791047 T AT 09791047T AT E546448 T1 ATE546448 T1 AT E546448T1
- Authority
- AT
- Austria
- Prior art keywords
- urotensin
- receptor antagonists
- compounds
- formula
- prodrugs
- Prior art date
Links
- 102000012327 Urotensin II receptors Human genes 0.000 title abstract 2
- 108050002984 Urotensin II receptors Proteins 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13763408P | 2008-08-02 | 2008-08-02 | |
| PCT/US2009/052403 WO2010017105A1 (en) | 2008-08-02 | 2009-07-31 | Urotensin ii receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE546448T1 true ATE546448T1 (de) | 2012-03-15 |
Family
ID=41259404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT09791047T ATE546448T1 (de) | 2008-08-02 | 2009-07-31 | Urotensin-ii-rezeptorantagonisten |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9079896B2 (de) |
| EP (1) | EP2326644B1 (de) |
| JP (1) | JP2011529966A (de) |
| AT (1) | ATE546448T1 (de) |
| CA (1) | CA2732762A1 (de) |
| ES (1) | ES2379762T3 (de) |
| WO (1) | WO2010017105A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008016534A1 (en) | 2006-07-31 | 2008-02-07 | Janssen Pharmaceutica, N.V. | Urotensin ii receptor antagonists |
| EP2686320B1 (de) * | 2011-03-15 | 2016-05-18 | Merck Sharp & Dohme Corp. | Tricyclische gyrase-inhibitoren |
| US9879016B2 (en) | 2015-04-17 | 2018-01-30 | Abbvie Inc. | Indazolones as modulators of TNF signaling |
| AR104291A1 (es) | 2015-04-17 | 2017-07-12 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| US20160304496A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3629266A (en) * | 1969-03-03 | 1971-12-21 | Miles Lab | (phenyl piperidino alkyl)3 4-dihydrocarbostyrils |
| US6546112B1 (en) * | 1993-11-18 | 2003-04-08 | Digimarc Corporation | Security document with steganographically-encoded authentication data |
| AU7449198A (en) | 1997-05-21 | 1998-12-11 | Japan Tobacco Inc. | Phthalimide derivatives and pharmaceutical containing said derivatives |
| EP0999208A4 (de) * | 1997-05-30 | 2001-08-08 | Meiji Seika Kaisha | Stickstoffhaltige heterozyklische verbindungen und heilmittel zu behandlung von hyperlipämie die diese enthalten |
| HUP0003761A3 (en) * | 1997-07-31 | 2001-04-28 | Celgene Corp Warren | Substituted alkanohydroxamic acids and pharmaceutical compositions containing them |
| US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| DE19933611A1 (de) | 1999-07-17 | 2001-01-18 | Aventis Res & Tech Gmbh & Co | Verfahren zur Herstellung von Aminen durch homogen katalysierte reduktive Aminierung von Carbonylverbindungen |
| WO2001045711A1 (en) * | 1999-12-21 | 2001-06-28 | Smithkline Beecham Corporation | Urotensin-ii receptor antagonists |
| GB0027705D0 (en) * | 2000-11-11 | 2000-12-27 | S P A | Novel compounds |
| US20040039017A1 (en) | 2000-12-11 | 2004-02-26 | Dashyant Dhanak | Urotensin-II receptor antagonists |
| DE10138140A1 (de) * | 2001-08-09 | 2003-02-20 | Degussa | Verfahren zur Herstellung von Aminen durch reduktive Aminierung von Carbonylverbindungen unter Transfer-Hydrierungsbedingungen |
| ES2251624T3 (es) | 2001-12-28 | 2006-05-01 | Acadia Pharmaceuticals Inc. | Analogos de la tetrahidroquinolina como los agonistas muscarinicos. |
| US6660736B2 (en) * | 2002-03-27 | 2003-12-09 | Hoffmann-La Roche Inc. | Phthalimido derivatives and a process for their preparation |
| GB0209244D0 (en) | 2002-04-23 | 2002-06-05 | Glaxo Group Ltd | Compounds |
| WO2003104216A1 (en) | 2002-06-10 | 2003-12-18 | Acadia Pharmaceuticals Inc. | Urotensin ii receptor modulators |
| DE10238865A1 (de) | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| WO2004078114A2 (en) | 2003-02-28 | 2004-09-16 | Encysive Pharmaceuticals Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists. |
| JP4713465B2 (ja) | 2003-03-12 | 2011-06-29 | セルジーン コーポレイション | 7−アミド−イソインドリル化合物およびその薬学的使用 |
| DE602004032522D1 (de) * | 2003-03-12 | 2011-06-16 | Celgene Corp | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung |
| TW200900399A (en) | 2003-10-01 | 2009-01-01 | Speedel Experimenta Ag | Organic compounds |
| WO2005034873A2 (en) | 2003-10-09 | 2005-04-21 | Smithkline Beecham Corporation | A method for reducing anti-neoplastic agent induced side-effects |
| WO2005056540A1 (en) * | 2003-12-08 | 2005-06-23 | Warner-Lambert Company Llc | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia |
| WO2005072226A2 (en) | 2004-01-19 | 2005-08-11 | Smithkline Beecham Corporation | Use of urotensin-ii receptor antagonists in the treatment of inflammatory bowel diseases |
| MXPA06012279A (es) * | 2004-04-23 | 2007-01-31 | Celgene Corp | Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar. |
| TW200613272A (en) * | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
| WO2007008541A2 (en) | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
| EP2392571A3 (de) * | 2005-07-29 | 2012-03-14 | F. Hoffmann-La Roche AG | Indol-3-yl-Carbonyl-Piperidin- und Piperazinderivate |
| TW200804347A (en) | 2006-01-10 | 2008-01-16 | Janssen Pharmaceutica Nv | Urotensin II receptor antagonists |
| WO2008016534A1 (en) * | 2006-07-31 | 2008-02-07 | Janssen Pharmaceutica, N.V. | Urotensin ii receptor antagonists |
| PA8782701A1 (es) | 2007-06-07 | 2009-01-23 | Janssen Pharmaceutica Nv | Antagonistas del receptor de urotensina ii |
-
2009
- 2009-07-31 AT AT09791047T patent/ATE546448T1/de active
- 2009-07-31 WO PCT/US2009/052403 patent/WO2010017105A1/en not_active Ceased
- 2009-07-31 CA CA2732762A patent/CA2732762A1/en not_active Abandoned
- 2009-07-31 JP JP2011522131A patent/JP2011529966A/ja not_active Ceased
- 2009-07-31 US US12/533,257 patent/US9079896B2/en not_active Expired - Fee Related
- 2009-07-31 EP EP09791047A patent/EP2326644B1/de not_active Not-in-force
- 2009-07-31 ES ES09791047T patent/ES2379762T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011529966A (ja) | 2011-12-15 |
| US9079896B2 (en) | 2015-07-14 |
| WO2010017105A1 (en) | 2010-02-11 |
| EP2326644B1 (de) | 2012-02-22 |
| US20100029616A1 (en) | 2010-02-04 |
| ES2379762T3 (es) | 2012-05-03 |
| EP2326644A1 (de) | 2011-06-01 |
| CA2732762A1 (en) | 2010-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE542813T1 (de) | 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren | |
| MX2011013884A (es) | Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas. | |
| BRPI0910182B8 (pt) | composto de fórmula (i), composição farmacêutica e uso de um composto | |
| GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| EA201200049A1 (ru) | 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17 | |
| EA201100503A1 (ru) | Глюкозидные производные и их применения | |
| EA201290183A1 (ru) | Бензодиазепиновый ингибитор бромодомена | |
| EA201291217A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ | |
| MY165113A (en) | Piperidinone carboxamide azaindane cgrp receptor antagonists | |
| GEP20135744B (en) | Quinuclidine carbonate derivatives and medicinal compositions containing the same | |
| BRPI1013821A8 (pt) | piridinas substituídas como antagonistas de ccr3. | |
| GEP20227397B (en) | Inhibitors of influenza viruses replication | |
| EA201000113A1 (ru) | Пиразольные соединения | |
| EA201001724A1 (ru) | Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов | |
| MA34069B1 (fr) | Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a) | |
| EA201270216A1 (ru) | Фармацевтический состав | |
| MX390264B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. | |
| EA201071329A1 (ru) | Диамидные производные адамантана и их применение | |
| PT2323972E (pt) | Compostos de tetraciclina substituídos com c7-flúor | |
| IN2014CN04530A (de) | ||
| MD4556C1 (ro) | Compuşi inhibitori ai activităţii catehol O-metiltransferazei | |
| EA200900924A1 (ru) | Циклизованные производные как ингибиторы eg-5 | |
| EA201190017A1 (ru) | Аминоэфирные производные алкалоидов и их медицинские композиции | |
| EA201101118A1 (ru) | Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина | |
| EA201170722A1 (ru) | Лактамы в качестве ингибиторов бета-секретазы |